Median OS almost 2 years in ES-SCLC with Tarlatamab+Durvalumab maintenance = practice changing!
➡️ Challenge remains implementing Tarlatamab broadly + equitably so that all patients with ES-SCLC may benefit from this revolutionary therapy.
@OncoAlert #ESMO26 @NEJM
302 浏览 · 7 赞 · 4 转发 · 1 回复
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgPresented at #ESMO26: In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: https://nej.md/4iveIgW @myESMO在 X 查看被引用的帖子
- Alfredo Addeo MD@Alfdoc2
@christine_lovly @OncoAlert @NEJM This is the by far the most impactful #ESMO26 study IMHO. The impact and implication are huge.
来源：Christine Lovly, MD, PhD, FASCO · x.com